ESCRS Homepage

January 2003
IN THIS ISSUE

Long-term SLT results promise ‘valuable’ primary treatment


Retinal transplantation trials for RP look set to begin

EU guidelines give optimal correction licence to fly

Treatment for retinal dystrophies near fruition

Blindness cases climb in 60 to 80 years age bracket

WHO initiative targets childhood blindness

Digitised retinopathy screening improves efficiency

New hypotheses emerge on causes of wet AMD

Cataract surgery on the couch: What the future holds

Dark adaptation offers clue to earlier AMD diagnosis

Smoking may cause blindness in 20% of over 50-year-olds, say studies

New 3-D monitor brings surgery into digital world

CrystaLens new focus for spectacle-free vision

Long-term ICL data promising but cataracts still concern

Tattered Serbian health
system draws on ECOSG in fight against blindness

Atonic pupil a rare
cosmetic problem in cataract patients

Harvard study confirms phaco safety in patients with blebs

Cryoanalgesia affords drug-free anaesthesia for phaco

Paediatric myopia still hangs in ‘nature-nurture’ balance

Orbscan II alternative to infrared pupillometry

Femtosecond laser microkeratome offers advantages of ‘precisely centred’ thin flaps

Anger as surgeons are ‘used as pawns’ in Nidek US legal action

Popular SKBM microkeratomes are
recalled as product line is terminated

Simulating womb greatly reduces ROP rate

Molecular biology insights bring new treatments to fore

FEATURES
From The Editor
Reflections on Refractive Surgery
In Your Good Books
An Eye On Travel
Bio-ophthalmology
Regulatory Matters



CrystaLens new focus for spectacle-free vision

By Roibeard O’hÉineacháin

NICE — A majority of cataract patients implanted with the CrystaLensTM (AT-45 C&C Vision) IOL can read comfortably without reading glasses whether they need distance correction or not, a Belgian ophthalmologist told the XX ESCRS Congress.
In a study involving 47 eyes of 25 cataract patients implanted with the CrystaLens accommodative IOL, only two of 22 patients who received the implants in both eyes required reading glasses after a follow-up of at least three months, Erik Mertens MD said.

“Implantation of the accommodative AT-45 IOL affords patients the ability to become less dependent on glasses after extracapsular cataract extraction compared to monofocal IOLs. The glare and halos seen with multifocal IOLs do not occur with this new IOL,” he noted.
Binocular UCVA was 20/25 or better in 91%; 20/32 or better in 95%; and 20/40 or better in all eyes. Near UCVA was J1 or better in 23%; J2 or better in 73%; and J3 or better in 91%.
Monocular UCVA was 20/25 or better in 74%; 20/32 or better in 89%; and 20/40 or better in all. Monocular near UCVA was J1 or better in 21%; J2 or better in 51%; and J3 or better in 83%.

Monocular distance corrected near vision was J1 or better in 16%; J2 or better in 38%; and J3 or better in 84%. Binocular distance corrected near vision was J1 or better in 41%; J2 or better in 71%; and J3 or better in 94%.
The CrystaLens has two hinged haptics with polyamide loops which become fixed in the capsule during capsular shrinkage in the early postoperative period.

After implantation, the contraction of the ciliary muscle causes an increased pressure on the vitreous, which in turn pushes the optic forward.
The IOL has a 4.5 mm optic and a total length of 10.5 mm. It is made of a third-generation silicone material (Biosil). The lens is currently under FDA evaluation and may be approved by the end of the year.
The prospective study involved 15 women and 10 men aged 57 to 83. All were able to achieve a BCVA of 20/30 or better preoperatively and had undergone no previous ocular surgery.

Most had less than 1.0 D of corneal astigmatism preoperatively but a few patients with greater than 1.0 D of cylinder did receive the IOLs. Correction of the pre-existing astigmatism was achieved by limbal relaxing incisions.
Dr Mertens and his associates performed extracapsular cataract extraction on all eyes and implantation of a CrystaLens IOL. They implanted the lens through a 3.2 mm to 3.5 mm clear corneal incision and a 4.0 mm to 6.0 mm capsulorhexis.
Prior to surgery they performed immersion biometry in 36 eyes and optical coherence tomography using the IOLMasterTM in 11 eyes.

All patients received one drop of atropine immediately after surgery to paralyse the ciliary muscle during the period of early capsular fibrosis.
“I found out that the best size of the capsulorhexis was 5.0 mm. In the beginning I did a smaller 4.0 mm capsulorhexis but sometimes I found that part of the anterior capsule would get behind the lens and another part would get in front of it.

“The result would be tilting. I also found that a larger 6.0 mm capsulorhexis was too large and now I perform a 5.0 mm. I am very happy with this approach,” he said.
Dr Mertens noted that it is important to inform patients that it can take up to a couple of months before they will be able to read well. He recommended forbidding patients from using reading glasses or other aids during that time to encourage the activity of the ciliary muscles.

“In our study 81% of eyes achieved J3 or better and were therefore much less dependent on reading glasses. The lens also provides good intermediate vision and card players are very pleased with that. Therefore we feel justified in describing the implantation of the CrystaLens as refractive lens surgery,” he added.

 

Top